Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures ...

Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

Glucot (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a “best efforts” ...

These are the upcoming stock splits for the week of February 3 to February 7, based on TipRanks’ Stock Splits Calendar. A stock ...

"I am honored to join the Company at this pivotal time as we advance our human clinical trials and create a strategic regulatory program for the CBGM," Williams stated regarding his new role at ...

ISO 13485 is also strongly recommended and widely used in the European Union. For more information about Glucotrack's CBGM, visit glucotrack.com . Information on the Company's website does not ...

For more information about Glucotrack’s CBGM, visit glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.

Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...